Moderna Says its Booster Increases Omicron Neutralizing Antibody Levels
Vaccine maker Moderna, which is at the forefront of developing messenger RNA (mRNA) therapeutics and vaccines, announced today that according
Read more
COVID-19
Coronavirus (COVID-19) pharmaceutical industry updates
Read the latest pharmaceutical industry press releases, news updates and articles on coronavirus COVID-19 medical treatment, therapies and drug and vaccine development.
AstraZeneca’s Evusheld Becomes First FDA Authorised Antibody Therapy to Prevent COVID-19
Evusheld, a long-acting antibody (LAAB) combination from AstraZeneca, has received emergency use authorisation (EUA) by the FDA in the United
Read more
Pfizer-BioNTech Vaccine Booster Offers Protection Against Omicron Early Study Shows
Preliminary laboratory studies have shown that three doses of the Pfizer-BioNTech COVID-19 Vaccine can neutralize the Omicron variant (B.1.1.529 lineage),
Read more
Vaccine Makers Pledge Fast Response Against Omicron Variant
Leading vaccine producers have stated that new vaccines will be developed if necessary to meet the demand of governments worldwide
Read more
CDC Recommends Pfizer and Moderna COVID-19 Boosters for All US Adults
The US Centers for Disease Control and Prevention (CDC) has recommended the use of COVID-19 vaccine boosters for everyone 18
Read more
Emergex to Launch Phase I Trial for New T-Cell Priming COVID-19 Vaccine
A next-generation COVID-19 vaccine, developed by British biotech Emergex, designed to prime T-Cells to rapidly remove viral-infected cells and offer
Read more
Japan to Buy 1.6 Mill Courses of Merck’s Oral COVID-19 Antiviral Molnupiravir
Merck (MRK) and Ridgeback Biotherapeutics have announced that the Japanese government will acquire approximately 1.6 million courses of molnupiravir (MK-4482,
Read more
J&J to Provide its One Dose COVID-19 Vaccine to the Most Vulnerable via COVAX Humanitarian Buffer
The world’s most vulnerable populations are given access to COVID-19 vaccines thanks to the COVAX Humanitarian Buffer. Johnson & Johnson
Read more
Pfizer’s COVID-19 Oral Antiviral Candidate 89% Effective in Phase 2/3 Study
The novel COVID-19 investigational oral antiviral treatment PAXLOVID™ (PF-07321332; ritonavir) by Pfizer, was found to reduce the risk of hospitalization
Read more
First Oral COVID-19 Antiviral Medicine Approved in the UK
Merck and Ridgeback’s Molnupiravir has become the world’s first approved oral COVID-19 antiviral drug. Molnupiravir has been authorised by the
Read more